Ken Griffin Scynexis Inc Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Scynexis Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 9,000 shares of SCYX stock, worth $9,990. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,000
Previous 10,300
12.62%
Holding current value
$9,990
Previous $15,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding SCYX
# of Institutions
53Shares Held
12.7MCall Options Held
9KPut Options Held
0-
Federated Hermes, Inc. Pittsburgh, PA2.9MShares$3.21 Million0.01% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY2.24MShares$2.48 Million0.42% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.66MShares$1.84 Million0.0% of portfolio
-
Avidity Partners Management LP Dallas, TX1.23MShares$1.36 Million0.16% of portfolio
-
Amh Equity LTD626KShares$694,9170.79% of portfolio
About SCYNEXIS INC
- Ticker SCYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 32,651,800
- Market Cap $36.2M
- Description
- SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...